Novakand Pharma AB (publ) (LARK) - Total Liabilities

Latest as of June 2026: Skr846.00K SEK ≈ $91.04K USD

Based on the latest financial reports, Novakand Pharma AB (publ) (LARK) has total liabilities worth Skr846.00K SEK (≈ $91.04K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Novakand Pharma AB (publ) (LARK) defensive interval to measure how many days the company can operate on defensive assets alone.

Novakand Pharma AB (publ) - Total Liabilities Trend (2012–2025)

This chart illustrates how Novakand Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check Novakand Pharma AB (publ) liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Novakand Pharma AB (publ) Competitors by Total Liabilities

The table below lists competitors of Novakand Pharma AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
Polar Power Inc NASDAQ:POLA	USA	$9.35 Million
Manchester and London Investment Trust plc LSE:MNL	UK	GBX111.87 Million
Kontigo Care AB ST:KONT	Sweden	Skr13.13 Million
Tourn International AB ST:TOURN	Sweden	Skr20.46 Million
Bang Overseas Limited NSE:BANG	India	Rs1.03 Billion
DomaCom Limited AU:DCL	Australia	AU$6.24 Million
Chenghe Acquisition II Co. NYSE MKT:CHEB	USA	$6.90 Million
Suvidhaa Infoserve Limited NSE:SUVIDHAA	India	Rs353.50 Million

Liability Composition Analysis (2012–2025)

This chart breaks down Novakand Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LARK total asset value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	8.85	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.01	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.01	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Novakand Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Novakand Pharma AB (publ) (2012–2025)

The table below shows the annual total liabilities of Novakand Pharma AB (publ) from 2012 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr1.24 Million ≈ $133.34K	-71.19%
2024-12-31	Skr4.30 Million ≈ $462.75K	+3.47%
2023-12-31	Skr4.16 Million ≈ $447.22K	-31.86%
2022-12-31	Skr6.10 Million ≈ $656.32K	-23.21%
2021-12-31	Skr7.94 Million ≈ $854.68K	-0.49%
2020-12-31	Skr7.98 Million ≈ $858.87K	-66.06%
2019-12-31	Skr23.51 Million ≈ $2.53 Million	+60.38%
2018-12-31	Skr14.66 Million ≈ $1.58 Million	+801.06%
2017-12-31	Skr1.63 Million ≈ $175.10K	+100.96%
2016-12-31	Skr809.66K ≈ $87.13K	+17.05%
2015-12-31	Skr691.73K ≈ $74.44K	+18.85%
2014-12-31	Skr582.04K ≈ $62.64K	+1320.21%
2013-12-31	Skr40.98K ≈ $4.41K	-86.18%
2012-12-31	Skr296.58K ≈ $31.92K	--

About Novakand Pharma AB (publ)

ST:LARK USA Asset Management

Market Cap

$4.79 Million

Skr44.55 Million SEK

Market Cap Rank

#28701 Global

#5872 in USA

Share Price

Skr2.25

Change (1 day)

+1.81%

52-Week Range

Skr1.84 - Skr2.56

All Time High

Skr2.56